Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Smart Nanofiber Therapy Effective in Fighting Cancer

By BiotechDaily International staff writers
Posted on 23 Jul 2013
Japanese scientists reported that integrating magnetic nanoparticles with an anticancer agent into crosslinked polymer nanofibers offers a twofold treatment for cancer therapy with lessened side effects.

Stimuli-responsive or “smart” polymeric nanofibers have spurred increasing interest. The nanoscale structures give rise to high sensitivity to stimuli while they can also be manipulated easily as macroscopic materials. Researchers from the Materials and Science Engineering Graduate School of Pure and Applied Science of the University of Tsukuba (Tsukuba, Japan) and the National Institute of Materials Science (NIMS; Tsukuba, Ibaraki, Japan) now have revealed how they can be used to utilize magnetic nanoparticles to enhance hyperthermal effects for treating cancer while avoiding the typical side-effects. The incorporation of doxorubicin in the nanofibers as well allows controlled release of the anticancer drug as a further mechanism for killing cancer cells.

Magnetic nanoparticles can kill cancer cells through the heat generated by induction when subjected to an alternating magnetic field. Such hyperthermal treatments have also been shown to improve the effectiveness of anticancer drugs. However, the nanoparticles can also lead to impaired mitochondrial function, inflammation, and DNA damage. Incorporating the nanoparticles into nanofibers may provide a better approach.

Drs. Young-Jin Kim, Mitsuhiro Ebara, and Takao Aoyagi electro-spun the fibers from a solution of the polymer poly(NIPAAm-co-HMAAm) mixed with a solution of magnetic nanoparticles and doxorubicin. The heating caused by the nanoparticles when switching on an alternating magnetic field caused hyperthermal effects, as well as reversible decreased swelling and deformation of the fibers, which released the drug molecules. In vitro and cell line research was shown to effectively destroy the cancer cells, which was greatly reduced for hyperthermal treatments alone in the absence of doxorubicin.

“The doxorubicin/magnetic-nanoparticles nanofiber induced the apoptosis of cancer cells due to a synergistic effect of chemotherapy and hyperthermia,” reported the authors, who published their findings online June 14, 2013, in the journal Advanced Functional Materials. The study demonstrates how smart nanofibers have potential for use as a manipulative material that combines hyperthermia and drug release treatments that can be controlled with the simple switching on or off of an alternating magnetic field.

Related Links:

University of Tsukuba
National Institute of Materials Science



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.